Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Top Cited Papers
Open Access
- 8 October 2025
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 31 (12) , 4205-4213
Abstract
In DESTINY-Breast04 (NCT03734029), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician’s choice of chemotherapy (TPC) for patients with human epidermal growth factor receptor 2-low (HER2-low) (immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative) metastatic breast cancer. After an extended median follow-up of 32.0 months, median OS in the overall cohort was 22.9 months for T-DXd and 16.8 months for TPC (hazard ratio 0.69; 95% confidence interval 0.55–0.86). For the hormone receptor-positive cohort, median OS was 23.9 and 17.6 months for T-DXd and TPC, respectively (hazard ratio 0.69; 95% confidence interval 0.55–0.87). Median OS also favored T-DXd in exploratory analyses of hormone receptor-negative, estrogen receptor IHC 1%–10% and estrogen receptor IHC >10% cohorts. The overall safety profile of T-DXd was acceptable and generally manageable. Results confirm T-DXd as standard of care after prior chemotherapy in patients with HER2-low metastatic breast cancer. ClinicalTrials.gov identifier: NCT03734029.Keywords
This publication has 31 references indexed in Scilit:
- Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohortAnnals of Oncology, 2021
- Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancernpj Breast Cancer, 2021
- The significance of highlighting the oestrogen receptor low category in breast cancerBritish Journal of Cancer, 2020
- HER2-Low Breast Cancer: Pathological and Clinical LandscapeJournal of Clinical Oncology, 2020
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline UpdateJournal of Clinical Oncology, 2020
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib StudyJournal of Clinical Oncology, 2020
- Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER DatabaseClinical Cancer Research, 2019
- The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer TherapyChemical and Pharmaceutical Bulletin, 2019
- Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-AnalysisClinical Breast Cancer, 2018
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1Clinical Cancer Research, 2016